Pruritus News and Research

RSS
Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Obeticholic acid meets primary composite endpoint in Phase III study

Obeticholic acid meets primary composite endpoint in Phase III study

OncoSec Medical to re-launch Phase II cutaneous T-cell lymphoma trial under protocol amendment

OncoSec Medical to re-launch Phase II cutaneous T-cell lymphoma trial under protocol amendment

FDA approves ORALAIR sublingual allergy immunotherapy tablet

FDA approves ORALAIR sublingual allergy immunotherapy tablet

SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis reports revenue of $1.25 billion for Q4 2013

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt announces commercial launch of PENNSAID

FDA approves New Drug Application for PENNSA 2%

FDA approves New Drug Application for PENNSA 2%

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review